轉染技術市場:現狀分析及預測(2022年～2028年)

轉染技術的市場規模，在預測期間內預計以約8％的年複合成長率擴大。轉染改變宿主細胞遺傳內容的能力在研究正常細胞過程、疾病的分子機制和基因治療的功效方面具有廣泛的應用。轉染作為遺傳基因或遺傳基因物產的功能和控制的研究，基因轉殖生物的生產，及基因治療的方法，成為強力的分析工具。

本報告提供全球轉染技術市場相關調查，市場概要，以及各類型，各用途，各技術，各終端用戶，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場簡介

第2章 調查方法或假設，市場定義

第3章 市場摘要

第4章 摘要整理

第5章 COVID-19對轉染技術市場的影響

第6章 轉染科技市場收益(10億美元)，2020年～2028年

第7章 各產品類型的市場洞察

• 試劑
• 設備
• 其他

第8章 各用途的市場洞察

• 治療藥給藥
• 生物醫學研究
• 蛋白質產生
• 其他

第9章 各技術的市場洞察

• 物理的轉染
• 生物化學為基礎的轉染
• 病毒載體為基礎的轉染

第10章 各終端用戶的市場洞察

• 研究中心、學術機構
• 醫院、診療所
• 製藥公司、生物科技企業
• 其他

第11章 各地區的市場洞察

• 北美
• 歐洲
• 亞太地區
• 其他地區

第12章 轉染技術市場動態

• 推動市場要素
• 市場課題
• 影響分析

第13章 轉染技術的市場機會

第14章 轉染技術的市場趨勢

第15章 需求面和供給方面的分析

第16章 價值鏈分析

第17章 競爭模式

第18章 公司概要

• Lonza Group Ltd.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Roche
• QIAGEN
• Mirus Bio LLC
• SignaGen Laboratories
• Genlantis Inc.
• OZ Biosciences
• Promega Corporation

第19章 免責聲明

The transfection technologies market is expected to witness a CAGR of around 8% during the forecast period. Transfection is a modern and powerful method used to insert foreign nucleic acids into eukaryotic cells. The ability to modify host cells' genetic content enables the broad application of this process in studying normal cellular processes, disease molecular mechanisms, and gene therapeutic effects. Biosimilar drug development is accelerated as several drug patents are anticipated to lapse in the coming years. A combination of cytological, genomic, and proteomic analysis is crucial to their development. As a result, the use of transfection equipment and reagents in proteomic and genomic research has grown. Furthermore, rising cases of cancer & high demand for synthetic genes will increase the growth of the transfection technologies market. For instance, according to the data provided by the International Agency for Research on Cancer (IRAC) in 2018, it is estimated that there will be more than 27.5 million new cancer cases by 2040. Also, the two main purposes of transfection are to produce recombinant proteins or to specifically enhance or inhibit gene expression in transfected cells. As such, transfection is a powerful analytical tool for the study of the function and regulation of genes or gene products, for the production of transgenic organisms, and as a method for gene therapy.

Based on product type, the market is segmented into reagents, instruments, and others. Among them, the reagent category is to witness lucrative growth during the forecast period. This growth can be attributed to factors like advancements in transfection technology, global alliances between leading research institutes to spur drug discovery, rising pharmaceutical and biotechnology companies' R&D spending and research activities, an increase in demand for synthetic genes, and a rise in the prevalence of cancer.

On the basis of application, the market is categorized into therapeutic delivery, bio-medical research, protein production, and others. Among these, the therapeutic delivery category is anticipated to register a lucrative CAGR during the forecast period. This is mainly due to the rising demand for precise therapeutic procedures and intensifying research and development activities associated with novel drug and transfection technique discoveries.

Based on technology, the transfection technologies market has been classified into physical transfection, biochemical-based transfection, and viral-vector-based transfection. The viral-vector-based transfection category to hold a significant share in the market during the forecast period. This is mainly due to the growing prominence of gene and cell therapy products and increasing funding activities are the key driving factors fueling the growth of the market.

Based on end-user, the transfection technologies market has been classified into research centers and academic institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and others. The pharmaceutical and biotechnology companies category is to witness higher adoption of transfection technologies during the forecast period. This is mainly due to the growing biopharmaceuticals and technological advancements that will drive the growth of the global transfection technologies market. Besides, the rising government funding to leading research institutes in developed countries for drug development will also drive the transfection technologies market.

For a better understanding of the market adoption of the transfection technologies market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the presence of cutting-edge research labs and leading pharmaceutical companies that are continuously contributing to research and development. The full-fledged economies of the states in North America force them to spend an incalculable amount of money on developing modern treatments. Additionally, the rising obesity and breast cancer rates in the US are the major contributor to this sector's dominance in the transfection technologies market. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer.

Some of the major players operating in the market include: Lonza Group Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Roche, QIAGEN, Mirus Bio LLC, SignaGen Laboratories, Genlantis Inc., OZ Biosciences, and Promega Corporation.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Transfection Technologies Market
• 2.2. Research Methodology of the Transfection Technologies Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE TRANSFECTION TECHNOLOGIES MARKET

6 TRANSFECTION TECHNOLOGIES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Reagent
• 7.2. Instrument
• 7.3. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Therapeutic Delivery
• 8.2. Bio-Medical Research
• 8.3. Protein Production
• 8.4. Others

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Physical Transfection
• 9.2. Biochemical-Based Transfection
• 9.3. Viral-Vector-Based Transfection

10 MARKET INSIGHTS BY END-USER

• 10.1. Research Centers and Academic Institutes
• 10.2. Hospitals and Clinics
• 10.3. Pharmaceutical and Biotechnology Companies
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 TRANSFECTION TECHNOLOGIES MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 TRANSFECTION TECHNOLOGIES MARKET OPPORTUNITIES

14 TRANSFECTION TECHNOLOGIES MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Lonza Group Ltd.
• 18.2. Thermo Fisher Scientific Inc.
• 18.3. Bio-Rad Laboratories Inc.
• 18.4. Roche
• 18.5. QIAGEN
• 18.6. Mirus Bio LLC
• 18.7. SignaGen Laboratories
• 18.8. Genlantis Inc.
• 18.9. OZ Biosciences
• 18.10. Promega Corporation

19 DISCLAIMER